{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:32:49Z","timestamp":1791153169238,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1007\/s11906-001-0046-2","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:02:26Z","timestamp":1180058546000},"page":"240-248","source":"Crossref","is-referenced-by-count":18,"title":["Aldosterone antagonists in the treatment of hypertension and target organ damage"],"prefix":"10.1007","volume":"3","author":[{"given":"Sanjay","family":"Rajagopalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Cerelli G, et al.: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268\u2013275.","journal-title":"Science"},{"key":"46_CR2","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1210\/mend-3-11-1877","volume":"3","author":"PD Patel","year":"1989","unstructured":"Patel PD, Sherman TG, Goldman DJ, Watson SJ:Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. Mol Endocrinol 1989, 3:1877\u20131885.","journal-title":"Mol Endocrinol"},{"key":"46_CR3","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1006\/bbrc.1995.2464","volume":"215","author":"T Trapp","year":"1995","unstructured":"Trapp T, Holsboer F: Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 1995, 215:286\u2013291.","journal-title":"Biochem Biophys Res Commun"},{"key":"46_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0039-128X(99)00087-2","volume":"65","author":"FM Rogerson","year":"2000","unstructured":"Rogerson FM, Fuller PJ: Mineralocorticoid action. Steroids 2000, 65:61\u201373.","journal-title":"Steroids"},{"key":"46_CR5","first-page":"597","volume":"7","author":"R Rupprecht","year":"1993","unstructured":"Rupprecht R, Arriza JL, Spengler D, et al.: Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol 1993, 7:597\u2013603.","journal-title":"Mol Endocrinol"},{"key":"46_CR6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583\u2013585.","journal-title":"Science"},{"key":"46_CR7","first-page":"135","volume":"18","author":"PC White","year":"1997","unstructured":"White PC, Mune T, Agarwal AK: 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrinol Rev 1997, 18:135\u2013156.","journal-title":"Endocrinol Rev"},{"key":"46_CR8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1210\/endo.135.3.8070376","volume":"135","author":"M Lombes","year":"1994","unstructured":"Lombes M, Kenouch S, Souque A, et al.: The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1994, 135:834\u2013840.","journal-title":"Endocrinology"},{"key":"46_CR9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1126\/science.8197458","volume":"264","author":"S Halachmi","year":"1994","unstructured":"Halachmi S, Marden E, Martin G, et al.: Estrogen receptorassociated proteins: possible mediators of hormone-induced transcription. Science 1994, 264:1455\u20131458.","journal-title":"Science"},{"key":"46_CR10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/bj2820697","volume":"282","author":"B Couette","year":"1992","unstructured":"Couette B, Lombes M, Baulieu EE, Rafestin-Oblin ME:Aldosterone antagonists destabilize the mineralocorticosteroid receptor. Biochem J 1992, 282:697\u2013702.","journal-title":"Biochem J"},{"key":"46_CR11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/bj3020191","volume":"302","author":"M Lombes","year":"1994","unstructured":"Lombes M, Binart N, Delahaye F, et al.: Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. Biochem J 1994, 302:191\u2013197.","journal-title":"Biochem J"},{"key":"46_CR12","first-page":"639","volume":"40","author":"H Hatakeyama","year":"1996","unstructured":"Hatakeyama H, Miyamori I, Takeda Y, et al.: The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int 1996, 40:639\u2013645.","journal-title":"Biochem Mol Biol Int"},{"key":"46_CR13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/bbrc.1994.2484","volume":"204","author":"M Wehling","year":"1994","unstructured":"Wehling M, Ulsenheimer A, Schneider M, et al.: Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium elevations by single cell imaging. Biochem Biophys Res Commun 1994, 204:475\u2013481.","journal-title":"Biochem Biophys Res Commun"},{"key":"46_CR14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1046\/j.1523-1755.2000.00980.x","volume":"57","author":"E Falkenstein","year":"2000","unstructured":"Falkenstein E, Christ M, Feuring M, Wehling M: Specific nongenomic actions of aldosterone. Kidney Int 2000, 57:1390\u20131394. Excellent review of the nongenomic effects of aldosterone.","journal-title":"Kidney Int"},{"key":"46_CR15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","volume":"76","author":"M Wehling","year":"1995","unstructured":"Wehling M, Neylon CB, Fullerton M, et al.: Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res 1995, 76:973\u2013979.","journal-title":"Circ Res"},{"key":"46_CR16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.21.6.929","volume":"21","author":"S Taddei","year":"1993","unstructured":"Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21:929\u2013933.","journal-title":"Hypertension"},{"key":"46_CR17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597. Favorable effects of aldosterone blockade on top of ACE inhibitors on endothelial function in patients with heart failure.","journal-title":"Circulation"},{"key":"46_CR18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/01.CIR.101.14.1722","volume":"101","author":"MJ Somers","year":"2000","unstructured":"Somers MJ, Mavromatis K, Galis ZS, Harrison DG: Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000, 101:1722\u20131728. Mineralocorticoids in the presence of salt alter endothelial function in a free radical-dependent manner.","journal-title":"Circulation"},{"key":"46_CR19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","volume":"125","author":"JW Funder","year":"1989","unstructured":"Funder JW, Pearce PT, Smith R, Campbell J: Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989, 125:2224\u20132226.","journal-title":"Endocrinology"},{"key":"46_CR20","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","volume":"269","author":"H Hatakeyama","year":"1994","unstructured":"Hatakeyama H, Miyamori I, Fujita T, et al.: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316\u20132420.","journal-title":"J Biol Chem"},{"key":"46_CR21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.HYP.25.2.170","volume":"25","author":"Y Takeda","year":"1995","unstructured":"Takeda Y, Miyamori I, Yoneda T, et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170\u2013173.","journal-title":"Hypertension"},{"key":"46_CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.HYP.29.1.45","volume":"29","author":"Y Takeda","year":"1997","unstructured":"Takeda Y, Miyamori I, Inaba S, et al.: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29:45\u201348.","journal-title":"Hypertension"},{"key":"46_CR23","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1210\/endo-129-6-3305","volume":"129","author":"BR Walker","year":"1991","unstructured":"Walker BR, Yau JL, Brett LP, et al.: 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology 1991, 129:3305\u20133312.","journal-title":"Endocrinology"},{"key":"46_CR24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1677\/joe.0.1650533","volume":"165","author":"F Xiao","year":"2000","unstructured":"Xiao F, Puddefoot JR, Vinson GP: Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol 2000, 165:533\u2013536. Evidence that hypertrophic effects of angiotensin can be mediated by aldosterone.","journal-title":"J Endocrinol"},{"key":"46_CR25","first-page":"40","volume":"52","author":"KHW Klein","year":"1963","unstructured":"Klein KHW: Klinisch-experimentelle untersuchungen uber den ein-flub von aldosteron auf hamodynamik und gerinnung. Z Kreisl Forsch 1963, 52:40\u201353.","journal-title":"Z Kreisl Forsch"},{"key":"46_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","volume":"71","author":"M Lombes","year":"1992","unstructured":"Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503\u2013510.","journal-title":"Circ Res"},{"key":"46_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00226785","volume":"154","author":"G Zhou","year":"1996","unstructured":"Zhou G, Kandala JC, Tyagi SC, et al.: Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 1996, 154:171\u2013178.","journal-title":"Mol Cell Biochem"},{"key":"46_CR28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovas Res 1997, 35:30\u201334.","journal-title":"Cardiovas Res"},{"key":"46_CR29","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000, 102:2700\u20132706. Substudy of RALES that shows that baseline levels of procollagen type III amino-terminal peptide are an important determinant of subsequent death and of death plus hospitalization and subsequent response to spironolactone.","journal-title":"Circulation"},{"key":"46_CR30","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","volume":"273","author":"JS Silvestre","year":"1998","unstructured":"Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883\u20134891.","journal-title":"J Biol Chem"},{"key":"46_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.med.48.1.231","volume":"48","author":"JW Funder","year":"1997","unstructured":"Funder JW: Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Ann Rev Med 1997, 48:231\u2013240.","journal-title":"Ann Rev Med"},{"key":"46_CR32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/jmcc.1996.0072","volume":"28","author":"SH Slight","year":"1996","unstructured":"Slight SH, Ganjam VK, Gomez-Sanchez CE, et al.: High affinity NAD(+)-dependent 11 beta-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 1996, 28:781\u2013787.","journal-title":"J Mol Cell Cardiol"},{"key":"46_CR33","first-page":"395","volume":"122","author":"Y Sun","year":"1993","unstructured":"Sun Y, Ratajska A, Zhou G, Weber KT: Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993, 122:395\u2013403.","journal-title":"J Lab Clin Med"},{"key":"46_CR34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/10641969709083193","volume":"19","author":"JW Funder","year":"1997","unstructured":"Funder JW: Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997, 19:885\u2013899.","journal-title":"Clin Exp Hypertens"},{"key":"46_CR35","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1210\/endo.141.5.7529","volume":"141","author":"Y Takeda","year":"2000","unstructured":"Takeda Y, Yoneda T, Demura M, et al.: Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000, 141:1901\u20131904.","journal-title":"Endocrinology"},{"key":"46_CR36","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","volume":"17","author":"A Benetos","year":"1997","unstructured":"Benetos A, Lacolley P, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997, 17:1152\u20131156.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"46_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","volume":"29","author":"E Belle Van","year":"1995","unstructured":"Van Belle E, Bauters C, Wernert N, et al.: Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 1995, 29:27\u201332.","journal-title":"Cardiovasc Res"},{"key":"46_CR38","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","volume":"99","author":"J-S Silvestre","year":"1999","unstructured":"Silvestre J-S, Heymes C, Oubenaissa A, et al.: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694\u20132701. Evidence for activation of the mineralocorticoid pathway in experimental infarction through an angiotensindependent mechanism.","journal-title":"Circulation"},{"key":"46_CR39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451\u2013458. Favorable effects of mineralocorticoid blockade in experimental hypertension.","journal-title":"Hypertension"},{"key":"46_CR40","unstructured":"Stier Jr C: Anti-oxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats [abstract]. Hypertension 2000, 4.03."},{"key":"46_CR41","doi-asserted-by":"crossref","first-page":"303A","DOI":"10.1016\/S0735-1097(01)80004-8","volume":"37","author":"S Rajagopalan","year":"2001","unstructured":"Rajagopalan S, Han Z, Venturini C, et al.: Selective aldosterone receptor antagonism improves endothelial function in diet induced atherosclerosis. J Am Coll Cardiol 2001, 37:303A.","journal-title":"J Am Coll Cardiol"},{"key":"46_CR42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","volume":"290","author":"U Ikeda","year":"1995","unstructured":"Ikeda U, Kanbe T, Nakayama I, et al.: Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 1995, 290:69\u201373.","journal-title":"Eur J Pharmacol"},{"key":"46_CR43","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/01.HYP.30.4.953","volume":"30","author":"Y Takeda","year":"1997","unstructured":"Takeda Y, Miyamori I, Yoneda T, et al.: Brain nitric oxide synthase messenger RNA in central mineralocorticoid hypertension. Hypertension 1997, 30:953\u2013956.","journal-title":"Hypertension"},{"key":"46_CR44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0960-0760(97)00004-6","volume":"61","author":"R Natarajan","year":"1997","unstructured":"Natarajan R, Lanting L, Bai W, et al.: The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells. J Steroid Biochem Mol Biol 1997, 61:47\u201353.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"46_CR45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/01.HYP.35.1.324","volume":"35","author":"CJ Hanke","year":"2000","unstructured":"Hanke CJ, O\u2019Brien T, Pritchard KA, Campbell WB: Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension 2000, 35:324\u2013328. Evidence for nitric oxide regulation of basal and stimulated adrenal aldosterone production.","journal-title":"Hypertension"},{"key":"46_CR46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.HYP.32.3.527","volume":"32","author":"M Usui","year":"1998","unstructured":"Usui M, Ichiki T, Katoh M, et al.: Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998, 32:527\u2013533.","journal-title":"Hypertension"},{"key":"46_CR47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0303-7207(99)00075-1","volume":"153","author":"EL Kreklau","year":"1999","unstructured":"Kreklau EL, Carlson EJ, Drewett JG: Nitric oxide inhibits human aldosteronogenesis without guanylyl cyclase stimulation. Mol Cell Endocrinol 1999, 153:103\u2013111.","journal-title":"Mol Cell Endocrinol"},{"key":"46_CR48","first-page":"336","volume":"85","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Kim KS, Chen YQ, et al.: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85:336\u2013344.","journal-title":"J Clin Endocrinol Metab"},{"key":"46_CR49","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","volume":"10","author":"J Blacher","year":"1997","unstructured":"Blacher J, Amah G, Girerd X, et al.: Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997, 10:1326\u20131334.","journal-title":"Am J Hypertens"},{"key":"46_CR50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","volume":"19","author":"DA Duprez","year":"1998","unstructured":"Duprez DA, De Buyzere ML, Rietzschel ER, et al.: Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients [see comments]. Eur Heart J 1998, 19:1371\u20131376.","journal-title":"Eur Heart J"},{"key":"46_CR51","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.HYP.35.4.931","volume":"35","author":"D Rizzoni","year":"2000","unstructured":"Rizzoni D, Porteri E, Guefi D, et al.: Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000, 35:931\u2013935.","journal-title":"Hypertension"},{"key":"46_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","volume":"22","author":"A Sato","year":"1999","unstructured":"Sato A, Suzuki Y, Saruta T: Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999, 22:17\u201322.","journal-title":"Hypertens Res"},{"key":"46_CR53","first-page":"I9899","volume":"98","author":"M MJ Epstein","year":"1998","unstructured":"Epstein M MJ, Alexander JC, et al.: Eplerinone, a novel and selective aldsterone receptor antagonist: efficacy in patients with mild to moderate hypertension. Circulation 1998, 98 (suppl):I9899.","journal-title":"Circulation"},{"key":"46_CR54","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/01.CIR.100.6.654","volume":"100","author":"S Takai","year":"1999","unstructured":"Takai S, Jin D, Sakaguchi M, et al.: Chymase-dependent angiotensin II formation in human vascular tissue [see comments]. Circulation 1999, 100:654\u2013658.","journal-title":"Circulation"},{"key":"46_CR55","doi-asserted-by":"crossref","unstructured":"Pitt B: \"Escape\" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995, 9:145\u2013149.","DOI":"10.1007\/BF00877755"},{"key":"46_CR56","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators [see comments]. Circulation 1999, 100:1056\u20131064.","journal-title":"Circulation"},{"key":"46_CR57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0039-128X(99)00087-2","volume":"65","author":"FM Rogerson","year":"2000","unstructured":"Rogerson FM, Fuller PJ: Mineralocorticoid action. Steroids 2000, 65:61\u201373.","journal-title":"Steroids"},{"key":"46_CR58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Remme WJ, Cody R, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709. Largest human trial to date to support mineralocorticoid blockade in heart failure. Impressive mortality and morbidity reductions with spironolactone.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-001-0046-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0046-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:04:33Z","timestamp":1628917473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-001-0046-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s11906-001-0046-2","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}